Ipamorelin is a peptide that acts at the ghrelin receptor. Research has examined hormone secretion and gastrointestinal motility; those findings do not establish the muscle-building or fat-loss claims of a particular product.
What the research shows
A 2014 randomized phase 2 trial in bowel-surgery patients found no significant differences in its key or secondary efficacy analyses. Earlier rodent findings therefore should not be presented as demonstrated human treatment benefits. [1] [2]
Distinguishing substances and products
Ipamorelin is distinct from an HGH product. Evidence or labeling for a CJC-1295/ipamorelin mixture cannot automatically describe an ipamorelin-only item; first identify the actual composition.
Reading a specific brand’s label
Start with the exact substance and product name, then match the label to the manufacturer’s documents. This article does not establish Thai registration or current availability for an unspecified product.
Frequently asked questions
Does this research prove muscle gain?
No. The cited clinical trial evaluated postoperative patients, not muscle gain from a marketed product.
Are ipamorelin and HGH interchangeable names?
No. They identify different substances; match the composition and documentation to the name.
What information helps identify a specific product?
The brand, product name, full label and matching manufacturer documents. Evidence about the substance alone does not establish a product’s identity, registration or quality.
Related information
For general questions about names or label details, contact LINE: @musclestationth
Sources and review date
- Beck et al., 2014 — postoperative ipamorelin trial
- Greenwood-Van Meerveld et al., 2009 — rodent motility study
Sources checked: 11 September 2026. This page explains selected primary sources; it is not a systematic review of every study.